Mathias Schmidt

Director/Board Member at JCR PHARMACEUTICALS CO., LTD.

56 year

Consumer Services

Health Technology

Health Services

Profile

Mathias Schmidt is currently the Chief Executive Officer & Director at ArmaGen, Inc. and MD, Head-Clinical & Business Development at JCR Pharmaceuticals Co., Ltd.
He is also the President & Chief Executive Officer at JCR USA, Inc. Dr. Schmidt holds a doctorate degree from the University of Freiburg and a graduate degree from Universität Stuttgart.

Mathias Schmidt active positions

Companies	Position	Start
JCR PHARMACEUTICALS CO., LTD.	Director/Board Member	31/05/2020
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Chief Executive Officer	-
JCR USA, Inc.	Chief Executive Officer	-

All active positions of Mathias Schmidt

Training of Mathias Schmidt

University of Freiburg	Doctorate Degree
Universität Stuttgart	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mathias Schmidt's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
JCR PHARMACEUTICALS CO., LTD.	Health Technology

Private companies	2
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Health Services
JCR USA, Inc.